Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about PFIZER
04:28p PFIZER INC. : Announces Pricing Terms of Private Exchange Offer for its 6.500 pe..
04:16p PFIZER : U.S. Food and Drug Administration Extends Action Date for XELJANZ Suppl..
04:16p CELLECTIS : - Preliminary Data from Servier and Pfizer's UCART19 Product Candida..
01:31p PFIZER : Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Developm..
09:01a SMI’S ADC CONFERENCE : Exclusive Pfizer Speaker Interview Released
12:02a PFIZER : FDA Approves New Pfizer Biosimilar
12/13 PFIZER : Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New..
12/13 SPARK THERAPEUTICS : and Pfizer Announce Longer-term Preliminary Data Showing Co..
12/13 PFIZER : Commissioners approve nearly $1.5 million incentive for Pfizer
12/12 PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tof..
12/12 Sanofi investors hungry for drug progress and deal news
12/12 PROTEOSTASIS THERAPEUTICS, INC. (NAS : PTI) Files An 8-K Departure of Directors ..
12/11 HERE’S WHAT JUST HAPPENED WITH : LJPC) and Pfizer Inc. (NYSE:PFE)
12/11 Stocks mixed bag
12/11 PFIZER : Big pharma's blockbuster tax cuts
More most relevant news
All news about PFIZER
08:08p PFIZER : Researchers' Work from Pfizer Focuses on Carboxylic Ester Hydrolases (A..
05:26p PFIZER : Updated Data from Phase 3 Trial of IBRANCE® palbociclib Plus Letrozole ..
04:28p PFIZER INC. : Announces Pricing Terms of Private Exchange Offer for its 6.500 pe..
04:16p PFIZER : U.S. Food and Drug Administration Extends Action Date for XELJANZ Suppl..
04:16p CELLECTIS : - Preliminary Data from Servier and Pfizer's UCART19 Product Candida..
01:31p PFIZER : Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Developm..
09:01a SMI’S ADC CONFERENCE : Exclusive Pfizer Speaker Interview Released
12:02a PFIZER : FDA Approves New Pfizer Biosimilar
12/13 PFIZER : Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New..
12/13 SPARK THERAPEUTICS : and Pfizer Announce Longer-term Preliminary Data Showing Co..
More news
Sector news : Pharmaceuticals - NEC
09:09p Wall Street falls as investors fret about tax bill passage
08:31p Perrigo lines up bid for Merck's consumer health unit - sources
04:44p TEVA PHARMACEUTICAL INDUSTRIES : Pharm to lay off a quarter of workforce, suspen..
03:11pDJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs, Suspend Dividend -- Update
02:01pDJTEVA PHARMACEUTICAL INDUSTRIES : to Cut 14,000 Jobs
11:42aDJGLAXOSMITHKLINE : GSK Applies for Australian Approval of Malaria Treatment
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:27a Pfizer launches Phase 3 program for JAK1 inhibitor PF-04965842 in atopic derm..
08:16a More Positives For Roche, The Core Biotech For The Long Run
04:07a YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Pfizer gets FDA nod for second biosimilar of J&J's Remicade
12/13 Can Adamis Bleed Mylan Dry?
12/13 Does Amphastar's Pipeline Warrant Its Valuation?
Financials ($)
Sales 2017 52 550 M
EBIT 2017 19 881 M
Net income 2017 10 958 M
Debt 2017 23 944 M
Yield 2017 3,48%
P/E ratio 2017 19,65
P/E ratio 2018 16,94
EV / Sales 2017 4,61x
EV / Sales 2018 4,48x
Capitalization 218 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 38,2 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER10.04%218 400
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214
AMGEN19.97%128 762